Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Kristina M BrooksParag Kumar

Abstract

Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection. This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and dolutegravir, a first-line antiretroviral medication. This was a single-center, open-label, fixed-sequence, drug-drug interaction study in healthy volunteers. Subjects received oral dolutegravir 50 mg once daily alone (days 1-4) and concomitantly with once-weekly isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19). Dolutegravir concentrations were measured on days 4, 14, and 19, and rifapentine, 25-desacetyl-rifapentine, and isoniazid concentrations were measured on day 19. Cytokines and antidrug antibodies to isoniazid and rifapentine were examined at select time points. The study was terminated following the development of flu-like syndrome and elevated aminotransferase levels in 2 of 4 subjects after the third isoniazid-rifapentine dose. Markedly elevated levels of interferon-γ, CXCL10, C-reactive protein, and other cytokines were temporally associated with symptoms. Antidrug antibodies were infrequently detected. Dolutegravir area under the curve (AUC) was decrease...Continue Reading

References

Oct 17, 1977·JAMA : the Journal of the American Medical Association·N F Jacobs, S E Thompson
Jul 1, 1983·Reviews of Infectious Diseases·J Grosset, S Leventis
Jan 18, 2003·American Journal of Respiratory and Critical Care Medicine·Marc WeinerUNKNOWN Tuberculosis Trials Consortium
Feb 14, 2004·American Journal of Respiratory and Critical Care Medicine·Marc WeinerUNKNOWN Tuberculosis Trials Consortium
Aug 16, 2006·The New England Journal of Medicine·Ganesh SuntharalingamNicki Panoskaltsis
Apr 22, 2009·Archives of Drug Information·Christophe SchmittSusan Grange
Dec 31, 2009·Journal of Immunotoxicology·Jinze LiJack Uetrecht
Jul 28, 2010·Antimicrobial Agents and Chemotherapy·Vanitha SekarRichard Hoetelmans
Mar 18, 2011·Clinical Pharmacology and Therapeutics·I G MetushiJ P Uetrecht
Jul 8, 2011·The New England Journal of Medicine·Neil A MartinsonRichard E Chaisson
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team
May 11, 2013·Lung India : Official Organ of Indian Chest Society·Sudipta PanditSibes K Das
Jun 19, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Imir G MetushiJack Uetrecht
Dec 18, 2013·The Journal of Antimicrobial Chemotherapy·Marc WeinerCharles A Peloquin
Aug 27, 2014·Antimicrobial Agents and Chemotherapy·Ivy SongStephen C Piscitelli
Apr 24, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy R SterlingUNKNOWN Tuberculosis Trials Consortium
Jun 18, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anthony T PodanyUNKNOWN AIDS Clinical Trials Group A5279 Study Team
Jun 23, 2015·Biological & Pharmaceutical Bulletin·Yoshihiko ShimokawaKen Umehara
Jun 1, 2016·AIDS·Timothy R SterlingUNKNOWN Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investi
Jul 13, 2016·JAMA : the Journal of the American Medical Association·Huldrych F GünthardPaul A Volberding
Apr 27, 2017·Toxicological Sciences : an Official Journal of the Society of Toxicology·Monday O OgeseDean J Naisbitt
Jun 3, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Amy L SandulChristine S Ho
Nov 9, 2017·Annals of Internal Medicine·Robert BelknapUNKNOWN TB Trials Consortium iAdhere Study Team

❮ Previous
Next ❯

Citations

Aug 7, 2018·Current Opinion in HIV and AIDS·Jeffrey A Tornheim, Kelly E Dooley
Feb 2, 2019·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoGiuliano Rizzardini
Mar 13, 2019·Pharmacotherapy·Kristina M BrooksDavid B Cluck
Jun 9, 2019·Journal of Clinical Medicine·Meng-Rui LeeInn-Wen Chong
May 31, 2019·Current Opinion in Allergy and Clinical Immunology·Jonny PeterRannakoe J Lehloenya
Dec 7, 2019·Expert Opinion on Drug Safety·Maddalena CerroneRobert J Wilkinson
Jan 17, 2020·The Journal of Antimicrobial Chemotherapy·Ismaeel EbrahimHelen McIlleron
Oct 5, 2018·Current Opinion in HIV and AIDS·Nathan FordHaileyesus Getahun
Jul 26, 2018·JAMA : the Journal of the American Medical Association·Michael S SaagPaul A Volberding
Sep 13, 2020·Current HIV/AIDS Reports·Elisa H Ignatius, Susan Swindells
Oct 5, 2018·Current Opinion in HIV and AIDS·Betina Durovni, Solange Cavalcante
Mar 14, 2019·The New England Journal of Medicine·Susan SwindellsUNKNOWN BRIEF TB/A5279 Study Team
Jul 6, 2019·The Lancet. HIV·Graeme MeintjesGary Maartens
Apr 5, 2021·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Lorenzo OnoratoNicola Coppola
Jul 30, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jyoti S MathadUNKNOWN IMPAACT 2001 Study Team

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

© 2021 Meta ULC. All rights reserved